It shows that virtually all respondents (98%) reported testing for ER/PR and HER2 status at diagnosis, while substantial majorities also tested at diagnosis for germline mutations (91%), including BRCA1/2 and PALB2, tumor PD-L1 expression (76%), and next generation sequencing (NGS) on tumor tissue (74%). This evidence concerns the gene ERBB2 and neoplasm.